Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Mar 19, 2024 4:37pm
105 Views
Post# 35941596

CSA Take-over rules

CSA Take-over rulesWhat are the rules for Take-over Bids in Canada?

"In general, unless exempt, a take-over bid must be made to all shareholders on identical terms (i.e. with no "collateral benefit" to any holder)  and all holders must be offered identical consideration (or the same choice of consideration) and the bid must be open for acceptance for at least 105 days."

Does this look fair and equtable to all shareholders ?  I think the CSA might be looking at this take-over.

The top 10 shareholders own 66% of the company.  If the are all aboard there is no way of stopping this.  The only shareholder that may be sour on this would be Yofoto that paid $5,090,005 for their 8.24%  share of the company.
<< Previous
Bullboard Posts
Next >>